Carlos David López‐Torres

Carlos David López‐Torres

Auto-generated profile, based on publicly available information

Carlos David López‐Torres

Laboratorio de Enfermedades Hepáticas Instituto Nacional de Medicina Genómica Ciudad de México Mexico

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2021 in Molecular Carcinogenesis
Verified
Journal Article
Open access
PDF file
MCMaría Paulette Castro‐Gil
María Paulette Castro‐Gil
RSRicardo Sánchez‐Rodríguez
Ricardo Sánchez‐Rodríguez
JTJulia Esperanza Torres‐Mena
Julia Esperanza Torres‐Mena
CLCarlos David López‐Torres
Carlos David López‐Torres
VQValeria Quintanar‐Jurado
Valeria Quintanar‐Jurado
JPJulio Isael Perez-Carreon
Julio Isael Perez-Carreon
The potential role of hepatocytes versus hepatic progenitor cells (HPC) on the onset and pathogenesis of hepatocellular carcinoma (HCC) has not been fully clarified. Because the administration of 2‐acetylaminofluorene (2AAF) followed by a partial hepatectomy, selectively induces the HPC proliferation, we investigated the effects of chronic 2AAF administration on the HCC development caused by the chronic administration of the carcinogen diethylnitrosamine (DEN) for 16 weeks in the rat. DEN + 2AAF protocol impeded weight gain of animals but promoted prominent hepatomegaly and exacerbated liver alterations compared to DEN protocol alone. The tumor areas detected by γ‐glutamyl transferase, prostaglandin reductase‐1, and glutathione S‐transferase Pi−1 liver cancer markers increased up to 80% as early as 12 weeks of treatment, meaning 6 weeks earlier than DEN alone. This protocol also increased the number of Ki67‐positive cells and those of CD90 and CK19, two well‐known progenitor cell markers. Interestingly, microarray analysis revealed that DEN + 2AAF protocol differentially modified the global gene expression signature and induced the differential expression of 30 genes identified as HPC markers as early as 6 weeks of treatment. In conclusion, 2AAF induces the early appearance of HPC markers and as a result, accelerates the hepatocarcinogenesis induced by DEN in the rat. Thus, since 2AAF simultaneously administrated with DEN enriches HPC during hepatocarcinogenesis, we propose that DEN + 2AAF protocol might be a useful tool to investigate the cellular origin of HCC with progenitor features.

24 July 2022 in The Journal of Gene Medicine
Verified
Journal Article
Closed access
CLCarlos David López‐Torres
Carlos David López‐Torres
JTJulia Esperanza Torres‐Mena
Julia Esperanza Torres‐Mena
MCMaría Paulette Castro‐Gil
María Paulette Castro‐Gil
STSaúl Villa Treviño
Saúl Villa Treviño
JAJaime Arellanes-Robledo
Jaime Arellanes-Robledo
JPJulio Isael Perez-Carreon
Julio Isael Perez-Carreon